IRD

#3307
Opus Genetics, Inc. - Common Stock
3.6 9 USD
-0.04%
Market Price
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
3.69
3.69
Faixa anual
2.82
5.81
Mudança diária
-4.16%
Mudança mensal
-4.16%
Mudança em 6 meses
-9.56%
Mudança anual
-0.81%
Fechamento anterior
3.8 5
Open
3.6 9
Mínimo
3.6 9
Máximo
3.6 9
Volume
59
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, 22 January 2013

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. on January 22, 2013. The filing discloses a significant change in executive leadership and the terms of a new employment agreement. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.

Key Financial Metrics

The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.

Material Changes

  • Executive Appointment: Dr. Peter D. Suzdak was appointed as Chief Executive Officer, effective February 4, 2013.
  • Role Transition: Dr. Chang Ahn will step down as CEO to serve as Chief Scientist and will remain Chairman of the Board.
  • Compensation Structure:
    • Annual base salary: $330,000.
    • Discretionary annual cash bonus: Up to 40% of base salary.
    • Equity grant: 1,200,000 stock options on the effective date, with potential for up to 500,000 additional options annually.

Guidance, Outlook, and Risks

The filing contains no financial guidance, market outlook, or discussion of general business risks. It details specific contractual contingencies regarding termination:

  • Termination without Cause/Good Reason: Triggers accelerated vesting of stock options, a lump sum payment equal to one year's base salary, pro-rata bonus, and 12 months of COBRA premiums.
  • Change of Control: If termination occurs within one year of a Change of Control, the lump sum payment increases to 200% of the annual base salary, plus tax gross-up.
  • Non-Solicitation: A 12-month restriction on soliciting executives, employees, customers, or clients post-termination.

Investor Verification Checklist

  • Verify the exact vesting schedule and exercise price for the 1,200,000 initial stock options granted to Dr. Suzdak.
  • Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change of Control."
  • Confirm the current cash position of Rexahn Pharmaceuticals to assess the impact of the new executive compensation package on liquidity.
  • Check for any subsequent filings regarding the transition of duties between Dr. Suzdak and Dr. Ahn.